A Phase 3 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-27.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 15th largest by enrollment, is one of 5 that started in 2012, is one of 11 in phase 3, and was the 14th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 15th largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2012, is one of 10 in phase 3, and was the 17th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This study provides subjects who complete the BEL113750 study and subjects who complete the open-label extension of HGS1006-C1115 (referred to as C1115) Study in Japan the option of continuing treatment with belimumab (10 mg/kg intravenously every 4 weeks) for those randomized to belimumab, or the option to begin treatment with belimumab for those randomized to placebo, as an add-on to their standard of care SLE therapy.
This is a multicentre, continuation study of belimumab plus standard of care (SOC) in SLE subjects who completed the Phase III BEL113750 protocol in Northeast Asia or who completed the open-label extension of the HGS1006-C1115 protocol in Japan. This study provides subjects who complete the BEL113750 study the option of continuing treatment with belimumab (10 mg/kg intravenously every 4 weeks) for those randomized to belimumab, or the option to begin treatment with belimumab for those randomized to placebo, as an add-on to their SOC SLE therapy. Subjects participating in this continuation protocol will continue to be monitored for safety and efficacy, as measured by the SLE responder index. Subjects who complete 48 weeks of treatment on the BEL113750 study and who meet inclusion/exclusion criteria, and provide informed consent, will be given the option to enter the continuation study. All subjects will receive belimumab 10 mg/kg IV infused over 1 hour every 4 weeks. Subjects recruited into this study will continue to receive treatment with belimumab until such time as belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
Drug: Belimumab
10 mg/kg administered intravenously over 1 hour every 4 weeks
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Any untoward medical occurrence in participant, temporally associated with use of medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death,life threatening,requires hospitalization or prolongation of existing hospitalization,results in disability/incapacity,congenital anomaly/birth defect,medically important were categorized as SAE. Number of participants who had any AE(includes those having non-serious and/or serious AEs) or any SAE are presented.Treatment-emergent AEs are defined as AEs that started on or after first dose of belimumab treatment and for those participants who were randomized to placebo in parent study,ongoing AEs that started before first open-label belimumab dose(in either C1115 open-label extension or BEL114333),worsened (severity,seriousness,relatedness) at any point during the open-label treatment.Timeframe includes exposure in parent study/upto16 weeks post infusion in current study(114333).
Time frame: Up to 6 calendar years and 9 months
Percentage of SLE Responder Index (SRI) Responders by Study Visit
SRI response is composite index, defined as percent of participants with\>=4 point reduction from Baseline in safety of estrogen in lupus national assessment systemic lupus erythematosus disease activity index (SELENA-SLEDAI) score and no worsening (increase of \<0.30 points from Baseline) in physicians global assessment(PGA) \&no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0(no activity) to 3(severe activity). BILAG has no range. Baseline is last available value prior to first belimumab exposure. Year 8 Week 24 visit is the Exit Visit obtained by slotting the Exit Visit to Week 24. Timeframe includes exposure in parent study/upto 4 weeks post infusion (Exit visit) in current study (114333).
Time frame: Study Years 1 to 7: At Week 24 and 48 Visits, Year 8: only Week 24 Visit
This was multicenter, open-label continuation study of belimumab plus standard of care (SOC) in Systemic Lupus Erythematosus (SLE) participants who completed study BEL113750 (NCT01345253) in Northeast Asia (Japan and Korea) \& participants who completed the open-label extension of C1115 (NCT01484496) in Japan to assess long term safety \& efficacy.
| Milestone | Open-label Belimumab 10 mg/kg |
|---|---|
| Started | 142 |
| Completed | 104 |
| Not completed | 38 |
| Withdrew: Adverse event | 7 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Investigator discretion | 5 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: Death | 1 |
Any untoward medical occurrence in participant, temporally associated with use of medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death,life threatening,requires hospitalization or prolongation of existing hospitalization,results in disability/incapacity,congenital anomaly/birth defect,medically important were categorized as SAE. Number of participants who had any AE(includes those having non-serious and/or serious AEs) or any SAE are presented.Treatment-emergent AEs are defined as AEs that started on or after first dose of belimumab treatment and for those participants who were randomized to placebo in parent study,ongoing AEs that started before first open-label belimumab dose(in either C1115 open-label extension or BEL114333),worsened (severity,seriousness,relatedness) at any point during the open-label treatment.Timeframe includes exposure in parent study/upto16 weeks post infusion in current study(114333).
| Participants | Open-label Belimumab 10 mg/kg |
|---|---|
| Any SAEs | 48 |
| Any AEs | 139 |
SRI response is composite index, defined as percent of participants with\>=4 point reduction from Baseline in safety of estrogen in lupus national assessment systemic lupus erythematosus disease activity index (SELENA-SLEDAI) score and no worsening (increase of \<0.30 points from Baseline) in physicians global assessment(PGA) \&no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0(no activity) to 3(severe activity). BILAG has no range. Baseline is last available value prior to first belimumab exposure. Year 8 Week 24 visit is the Exit Visit obtained by slotting the Exit Visit to Week 24. Timeframe includes exposure in parent study/upto 4 weeks post infusion (Exit visit) in current study (114333).
| Percentage of Participants | Open-label Belimumab 10 mg/kg |
|---|---|
| Year 1 Week 24, n=136 | 47.8 |
| Year 1, Week 48, n=133 | 51.1 |
| Year 2, Week 24, n=129 | 55.0 |
| Year 2, Week 48, n=121 | 53.7 |
| Year 3, Week 24, n=103 | 57.3 |
| Year 3, Week 48, n=88 | 68.2 |
| Year 4, Week 24, n=80 | 67.5 |
| Year 4, Week 48, n=60 | 76.7 |
| Year 5, Week 24, n=32 | 71.9 |
| Year 5, Week 48, n=29 | 69.0 |
| Year 6, Week 24, n=24 | 66.7 |
| Year 6, Week 48, n=22 | 68.2 |
| Year 7, Week 24, n=18 | 83.3 |
| Year 7, Week 48, n=13 | 84.6 |
| Year 8, Week 24, n=1 | 100 |
Collected over Treatment-emergent SAEs and non-serious AEs were collected up to maximum duration of 6 calendar years and 9 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Belimumab 10 mg/kg | 1/142 (0.7%) | 48/142 (33.8%) | 134/142 (94.4%) |
| Event | Open-label Belimumab 10 mg/kg |
|---|---|
| CellulitisInfections and infestations | 3/142 |
| Herpes zosterInfections and infestations | 3/142 |
| ContusionInjury, poisoning and procedural complications | 3/142 |
| EndocarditisInfections and infestations | 2/142 |
| Pyelonephritis acuteInfections and infestations | 2/142 |
| PyrexiaGeneral disorders | 2/142 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/142 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 2/142 |
| Abscess jawInfections and infestations | 1/142 |
| Atypical pneumoniaInfections and infestations | 1/142 |
| Event | Open-label Belimumab 10 mg/kg |
|---|---|
| NasopharyngitisInfections and infestations | 86/142 |
| HeadacheNervous system disorders | 40/142 |
| CoughRespiratory, thoracic and mediastinal disorders | 26/142 |
| Viral upper respiratory tract infectionInfections and infestations | 25/142 |
| Herpes zosterInfections and infestations | 23/142 |
| Abdominal pain upperGastrointestinal disorders | 23/142 |
| NauseaGastrointestinal disorders | 23/142 |
| Upper respiratory tract infectionInfections and infestations | 22/142 |
| DiarrhoeaGastrointestinal disorders | 22/142 |
| InfluenzaInfections and infestations | 20/142 |
Baseline is the last available value prior to the first belimumab exposure.
| Age, Continuous(Years) | Open-label Belimumab 10 mg/kg |
|---|---|
| Mean | 34.6 ± 9.28 |
| Sex: Female, Male(Participants) | Open-label Belimumab 10 mg/kg |
|---|---|
| Female | 129 |
| Male | 13 |
| Race/Ethnicity, Customized(Participants) | Open-label Belimumab 10 mg/kg |
|---|---|
| American Indian or Alaskan Native | 1 |
| Japanese Heritage | 71 |
| East Asian Heritage | 68 |
| Southeast Asian Heritage | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2012 to primary completion in Sep 2018, 75 months.
Results were first posted in Jan 2020, 1 year 3 months after primary completion.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 75 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →